Immunological alterations mediated by adenosine during host-microbial interactions

Immunologic Research

Volumn 50, Issue 1, 2011, Pages 69-77

  Drygiannakis, Ioannis ^a   Ernst, Peter B ^a,b   Lowe, David ^b   Glomski, Ian J ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Adenosine; Adenosine receptor; Dendritic cell; Immune evasion; Lymphocyte; Macrophage

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE DEAMINASE; CALCIUM; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; AEROMONAS; ANTIGEN PRESENTING CELL; BACILLUS ANTHRACIS; CALCIUM METABOLISM; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL SECRETION; CELL SURVIVAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GRAM POSITIVE BACTERIUM; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; NATURAL KILLER T CELL; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL; UPREGULATION;

ADENOSINE; ANIMALS; BACTERIA; BACTERIAL INFECTIONS; EXTRACELLULAR SPACE; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY; RECEPTORS, PURINERGIC P1; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 79955605126     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12026-011-8207-0     Document Type: Review

References (96)

1. Sitkovsky MV, Lukashev D, Apasov S, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol. 2004;22:657-82. (Pubitemid 38680437)
2. Atarashi K, Nishimura J, Shima T, et al. ATP drives lamina propria T(H)17 cell differentiation. Nature. 2008;455:808-12.
3. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol. 2001;41:775-87. (Pubitemid 32385906)
4. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204:1257-65. (Pubitemid 46919862)
5. Borsellino G, Kleinewietfeld M, DiMitri D, et al. Expression of ectonucleotidase CD39 by Foxp3 + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110:1225-32. (Pubitemid 47281420)
6. Alam MS, Kurtz CC, Rowlett RM, et al. CD73 is expressed by human regulatory T helper cells and suppresses proinflammatory cytokine production and Helicobacter felis-induced gastritis in mice. J Infect Dis. 2009;199:494-504.
7. Vukmanovic-Stejic M, Agius E, Booth N, et al. The kinetics of CD4 + Foxp3 + T cell accumulation during a human cutaneous antigen-specific memory response in vivo. J Clin Invest. 2008;118:3639-50.
8. Lukashev D, Sitkovsky M, Ohta A. From "Hellstrom Paradox" to anti-adenosinergic cancer immunotherapy. Purinergic Signal. 2007;3:129-34.
9. Thammavongsa V, Kern JW, Missiakas DM, Schneewind O. Staphylococcus aureus synthesizes adenosine to escape host immune responses. J Exp Med. 2009;206:2417-27.
10. Maier SA, Galellis JR, McDermid HE. Phylogenetic analysis reveals a novel protein family closely related to adenosine deaminase. J Mol Evol. 2005;61:776-94. (Pubitemid 41706026)
11. Weihofen WA, Liu J, Reutter W, Saenger W, Fan H. Crystal structure of CD26/dipeptidyl-peptidase IV in complex with adenosine deaminase reveals a highly amphiphilic interface. J Biol Chem. 2004;279:43330-5. (Pubitemid 39372228)
12. Pacheco R, Martinez-Navio JM, Lejeune M, et al. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc Natl Acad Sci U S A. 2005;102:9583-8. (Pubitemid 40981724)
13. Zavialov AV, Engstrom A. Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem J. 2005;391:51-7. (Pubitemid 41445475)
14. Zavialov AV, Gracia E, Glaichenhaus N, Franco R, Zavialov AV, Lauvau G. Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol. 2010;88:279-90.
15. Armstrong JM, Chen JF, Schwarzschild MA, et al. Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice. Biochem J. 2001;354:123-30. (Pubitemid 32183452)
16. Koshiba M, Kojima H, Huang S, Apasov S, Sitkovsky MV. Memory of extracellular adenosine A2A purinergic receptor-mediated signaling in murine T cells. J Biol Chem. 1997;272:25881-9. (Pubitemid 27438913)
17. Roscioni SS, Elzinga CR, Schmidt M. Epac: effectors and biological functions. Naunyn Schmiedebergs Arch Pharmacol. 2008;377:345-57.
18. Cheng X, Ji Z, Tsalkova T, Mei F. Epac and PKA: a tale of two intracellular cAMP receptors. Acta Biochim Biophys Sin (Shanghai). 2008;40:651-62. (Pubitemid 352009080)
19. Linden J. New insights into the regulation of inflammation by adenosine. J Clin Invest. 2006;116:1835-7. (Pubitemid 44033306)
20. Koshiba M, Rosin DL, Hayashi N, Linden J, Sitkovsky MV. Patterns of A2A extracellular adenosine receptor expression in different functional subsets of human peripheral T cells. Flow cytometry studies with anti-A2A receptor monoclonal antibodies. Mol Pharmacol. 1999;55:614-24.
21. Huang S, Apasov S, Koshiba M, Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood. 1997;90:1600-10. (Pubitemid 27355433)
22. Ohta A, Gorelik E, Prasad SJ, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA. 2006;103:13132-7. (Pubitemid 44338928)
23. Alam MS, Kurtz CC, Wilson JM, et al. A2A adenosine receptor (AR) activation inhibits pro-inflammatory cytokine production by human CD4 + helper T cells and regulates Helicobacter-induced gastritis and bacterial persistence. Mucosal Immunol. 2009;2:232-42.
24. Lappas CM, Rieger JM, Linden J. A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4 + T cells. J Immunol. 2005;174:1073-80. (Pubitemid 40094304)
25. Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008;7:759-70.
26. Ernst PB, Garrison JC, Thompson LF. Much ado about adenosine. Adenosine synthesis and function in regulatory T cell biology. J Immunol. 2010;185:1993-8.
27. Wilson JM, Ross WG, Agbai ON, et al. The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells. J Immunol. 2009;182:4616-23.
28. Yang M, Ma C, Liu S, et al. HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2-stimulating phenotype under hypoxia. Immunol Cell Biol. 2009;88:165-71.
29. Kong T, Westerman KA, Faigle M, Eltzschig HK, Colgan SP. HIF-dependent induction of adenosine A2B receptor in hypoxia. FASEB J. 2006;20:2242-50. (Pubitemid 44953854)
30. Nowak M, Lynch L, Yue S, et al. The A2aR adenosine receptor controls cytokine production in iNKT cells. Eur J Immunol. 2010;40:682-7.
31. Desrosiers MD, Cembrola KM, Fakir MJ, et al. Adenosine deamination sustains dendritic cell activation in inflammation. J Immunol. 2007;179:1884-92.
32. Dickenson JM, Reeder S, Rees B, Alexander S, Kendall D. Functional expression of adenosine A2A and A3 receptors in the mouse dendritic cell line XS-106. Eur J Pharmacol. 2003;474:43-51. (Pubitemid 37289144)
33. Hasko G, Nemeth ZH, Vizi ES, Salzman AL, Szabo C. An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-gamma production and prevents lethality in endotoxemic mice. Eur J Pharmacol. 1998;358:261-8. (Pubitemid 28498186)
34. Kreckler LM, Wan TC, Ge ZD, Auchampach JA. Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther. 2006;317:172-80.
35. Ren T, Grants I, Alhaj M, et al. Impact of disrupting adenosine A(3) receptors (A(3) (-/-)AR) on colonic motility or progression of colitis in the mouse. Inflamm Bowel Dis. 2010. doi: 10.1002/ibd.21553
36. Day YJ, Marshall MA, Huang L, McDuffie MJ, Okusa MD, Linden J. Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: inhibition of chemokine induction. Am J Physiol Gastrointest Liver Physiol. 2004;286:G285-93.
37. Day YJ, Huang L, McDuffie MJ, et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest. 2003;112:883-91. (Pubitemid 38063746)
38. Rork TH, Wallace KL, Kennedy DP, Marshall MA, Lankford AR, Linden J. Adenosine A2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation. Am J Physiol Heart Circ Physiol. 2008;295:H1825-33.
39. Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med. 2006;203:2639-48. (Pubitemid 44833340)
40. Panther E, Corinti S, Idzko M, et al. Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood. 2003;101:3985-90. (Pubitemid 36857876)
41. Hasko G, Kuhel DG, Chen JF, et al. Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J. 2000;14:2065-74.
42. Linnemann C, Schildberg FA, Schurich A, et al. Adenosine regulates CD8 T-cell priming by inhibition of membraneproximal T-cell receptor signalling. Immunology. 2009;128:e728-37.
43. Ring S, Oliver SJ, Cronstein BN, Enk AH, Mahnke K. CD4 + CD25 + regulatory T cells suppress contact hypersensitivity reactions through a CD39, adenosine-dependent mechanism. J Allergy Clin Immunol. 2009;123:1287-96.
44. Sevigny CP, Li L, Awad AS, et al. Activation of adenosine 2A receptors attenuates allograft rejection and alloantigen recognition. J Immunol. 2007;178:4240-9. (Pubitemid 46492374)
45. Climent N, Martinez-Navio JM, Gil C, et al. Adenosine deaminase enhances T-cell response elicited by dendritic cells loaded with inactivated HIV. Immunol Cell Biol. 2009;87:634-9.
46. Zarek PE, Huang CT, Lutz ER, et al. A2A receptor signaling promotes peripheral tolerance by inducing T cell anergy and the generation of adaptive regulatory T cells. Blood. 2008;111:251-9.
47. Chehata VJ, Domeier PP, Weilnau JN, Lappas CM. Adenosine A(2A) receptor activation limits chronic granulomatous disease-induced hyperinflammation. Cell Immunol. 2011;267:39-49.
48. Odashima M, Otaka M, Jin M, et al. A selective adenosine A2A receptor agonist, ATL-146e, prevents concanavalin A-induced acute liver injury in mice. Biochem Biophys Res Commun. 2006;347:949-54. (Pubitemid 44118210)
49. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 2001;414:916-20. (Pubitemid 34024743)
50. Csoka B, Himer L, Selmeczy Z, et al. Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J. 2008;22:3491-9.
51. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5′-adenosine monophosphate to adenosine. J Immunol. 2006;177:6780-6. (Pubitemid 44715042)
52. Yip L, Cheung CW, Corriden R, Chen Y, Insel PA, Junger WG. Hypertonic stress regulates T-cell function by the opposing actions of extracellular adenosine triphosphate and adenosine. Shock. 2007;27:242-50.
53. 2A receptors in the T cell mediated regulation of colitis. J Immunol. 2006;177:2765-9.
54. Raskovalova T, Lokshin A, Huang X, et al. Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling. Cancer Res. 2007;67:5949-56. (Pubitemid 46985031)
55. Ohta A, Ohta A, Madasu M, et al. A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol. 2009;183:5487-93.
56. Parish ST, Kim S, Sekhon RK, Wu JE, Kawakatsu Y, Effros RB. Adenosine deaminase modulation of telomerase activity and replicative senescence in human CD8 T lymphocytes. J Immunol. 2010;184:2847-54.
57. Ohta A, Kjaergaard J, Sharma S, et al. In vitro induction of T cells that are resistant to A(2) adenosine receptor-mediated immunosuppression. Br J Pharmacol. 2008;156:306.
58. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL. Phenotypically distinct subsets of CD4 + T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol. 1993;5:1461-71.
59. + T cells. Immunity. 1994;1:553-62.
60. Mandapathil M, Lang S, Gorelik E, Whiteside TL. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods. 2009;346:55-63.
61. Fletcher JM, Lonergan R, Costelloe L, et al. CD39+ Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol. 2009;183:7602-10.
62. Zhou Q, Yan J, Putheti P, et al. Isolated CD39 expression on CD4+ T cells denotes both regulatory and memory populations. Am J Transpl. 2009;9:2303-11.
63. Mandapathil M, Hilldorfer B, Szczepanski MJ, et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFoxp3+ regulatory T cells. J Biol Chem. 2010;285:7176-86.
64. Bynoe MS, Viret C. Foxp3+CD4+ T cell-mediated immunosuppression involves extracellular nucleotide catabolism. Trends Immunol. 2008;29:99-102.
65. Mandapathil M, Szczepanski MJ, Szajnik M, et al. Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem. 2010;285:27571-80.
66. Jin D, Fan J, Wang L, et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 2010;70:2245-55.
67. Hilchey SP, Kobie JJ, Cochran MR, et al. Human follicular lymphoma CD39 + -infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness. J Immunol. 2009;183:6157-66.
68. Falkow S. What is a pathogen? ASM News. 1997;63:359-65.
69. Cavalcante IC, Castro MV, Barreto ARF, et al. Effect of a novel A2A adenosine receptor agonist (ATL 313) on Clostridium difficile toxin induced murine ileal enteritis. Infect Immun. 2006;74:2606-12. (Pubitemid 43672968)
70. Sullivan GW, Fang G, Linden J, Scheld WM. A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis. J Infect Dis. 2004;189:1897-904. (Pubitemid 38657226)
71. Nemeth ZH, Csoka B, Wilmanski J, et al. Adenosine A2A receptor inactivation increases survival in polymicrobial sepsis. J Immunol. 2006;176:5616-26.
72. Suerbaum S, Josenhans C. Helicobacter pylori evolution and phenotypic diversification in a changing host. Nat Rev Microbiol. 2007;5:441-52. (Pubitemid 46780081)
73. Ernst PB, Peura DA, Crowe SE. The translation of Helicobacter pylori basic research to patient care. Gastroenterology. 2006;130:188-206. (Pubitemid 43049849)
74. Algood HM, Cover TL. Helicobacter pylori persistence: an overview of interactions between H. pylori and host immune defenses. Clin Microbiol Rev. 2006;19:597-613. (Pubitemid 44582973)
75. Blaser MJ. The biology of cag in the Helicobacter pylori-human interaction. Gastroenterology. 2005;128:1512-5. (Pubitemid 40712200)
76. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Invest. 2007;117:60-9. (Pubitemid 46048450)
77. Flores J, Okhuysen PC. Genetics of susceptibility to infection with enteric pathogens. Curr Opin Infect Dis. 2009;22:471-6.
78. Bouma MG, Jeunhomme TM, Boyle DL, et al. Adenosine inhibits neutrophil degranulation in activated human whole blood: involvement of adenosine A2 and A3 receptors. J Immunol. 1997;158:5400-8. (Pubitemid 127681247)
79. Firestein GS, Bullough DA, Erion MD, et al. Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor. The role of selectins. J Immunol. 1995;154:326-34.
80. Kaufmann I, Hoelzl A, Schliephake F, et al. Effects of adenosine on functions of polymorphonuclear leukocytes from patients with septic shock. Shock. 2007;27:25-31. (Pubitemid 44968006)
81. Ireland JA, Hanna PC. Macrophage-enhanced germination of Bacillus anthracis endospores requires gerS. Infect Immun. 2002;70:5870-2.
82. Kang TJ, Fenton MJ, Weiner MA, et al. Murine macrophages kill the vegetative form of Bacillus anthracis. Infect Immun. 2005;73:7495-501. (Pubitemid 41587654)
83. Crane JK, Shulgina I, Naeher TM. Ecto-5′-nucleotidase and intestinal ion secretion by enteropathogenic Escherichia coli. Purinergic Signal. 2007;3:233-46.
84. Fujii Y, Nomura T, Yokoyama R, Shinoda S, Okamoto K. Studies of the mechanism of action of the aerolysin-like hemolysin of Aeromonas sobria in stimulating T84 cells to produce cyclic AMP. Infect Immun. 2003;71:1557-60. (Pubitemid 36254345)
85. Gabriel SE, Brigman KN, Koller BH, Boucher RC, Stutts MJ. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science. 1994;266:107-9. (Pubitemid 24345328)
86. Strohmeier GR, Reppert SM, Lencer WI, Madara JL. The A2b adenosine receptor mediates cAMP responses to adenosine receptor agonists in human intestinal epithelia. J Biol Chem. 1995;270:2387-94.
87. Punj V, Zaborina O, Dhiman N, Falzari K, Bagdasarian M, Chakrabarty AM. Phagocytic cell killing mediated by secreted cytotoxic factors of Vibrio cholerae. Infect Immun. 2000;68:4930-7.
88. Melnikov A, Zaborina O, Dhiman N, Prabhakar BS, Chakrabarty AM, Hendrickson W. Clinical and environmental isolates of Burkholderia cepacia exhibit differential cytotoxicity towards macrophages and mast cells. Mol Microbiol. 2000;36:1481-93.
89. Zaborina O, Misra N, Kostal J, et al. P2Z-independent and P2Z receptor-mediated macrophage killing by Pseudomonas aeruginosa isolated from cystic fibrosis patients. Infect Immun. 1999;67:5231-42. (Pubitemid 29455296)
90. Akoachere M, Squires RC, Nour AM, Angelov L, Brojatsch J, bel-Santos E. Identification of an in vivo inhibitor of Bacillus anthracis spore germination. J Biol Chem. 2007;282:12112-8. (Pubitemid 47100689)
91. Glomski IJ, Piris-Gimenez A, Huerre M, Mock M, Goossens PL. Primary involvement of pharynx, peyer's patch in inhalational, intestinal anthrax. PLoS Pathog. 2007;3:e76.
92. Sanz P, Teel LD, Alem F, Carvalho HM, Darnell SC, O'Brien AD. Detection of Bacillus anthracis spore germination in vivo by bioluminescence imaging. Infect Immun. 2008;76:1036-47. (Pubitemid 351428063)
93. Cote CK, Bozue J, Twenhafel N, Welkos SL. Effects of altering the germination potential of Bacillus anthracis spores by exogenous means in a mouse model. J Med Microbiol. 2009;58:816-25.
94. Kolachala VL, Vijay-Kumar M, Dalmasso G, et al. A2B adenosine receptor gene deletion attenuates murine colitis. Gastroenterology. 2008;135:861-70.
95. Kolachala V, Ruble B, Vijay-Kumar M, et al. Blockade of adenosine A2B receptors ameliorates murine colitis. Br J Pharmacol. 2008;155:127-37.
96. Moore CC, Martin EN, Lee GH, Obrig T, Linden J, Scheld WM. An A2A adenosine receptor agonist, ATL313, reduces inflammation, improves survival in murine sepsis models. BMC Infect Dis. 2008;8:141.